T he mechanisms underlying the pathogenesis of inflammatory bowel disease (IBD) are not fully understood. 1 Although the recent advent of genome-wide association studies have unambiguously implicated several genes/loci, these do not explain the risk in full. 2 Several environmental factors have also been linked to the pathogenesis of IBD. Akin to cigarette smoking, antibiotics use and dysbiosis of the bacterial microbiome, there is evidence pointing to the role of certain viruses in IBD onset. 1, 3 Importantly, in animal models, certain eukaryotic viruses have been shown to interact with IBD risk genes. 4 Very little data exist regarding viral prevalence and viral load among patients with IBD. The most investigated viral candidates have been the cytomegalovirus (CMV), the Epstein-Barr virus (EBV), and the measles virus. [5] [6] [7] Both CMV and EBV, members of the Herpesviridae family, are acquired early in life, usually asymptomatic, and remain latent lifelong in healthy people. 8 It is well known that under immunosuppression these viruses may give rise to symptomatic infections. 9 IBD has been associated with a higher prevalence of EBV and CMV infection, being disputed whether they are really involved in the pathogenesis of the disease, associated with disease flares, complications, and response to therapy or are innocent bystanders. 5, 6 On the other hand, the increasing use of immunosuppressive therapies, associated with an increased risk of opportunistic infections 10 had led to a recrudescence of interest on their role on IBD. Despite all the evidence linking EBV and CMV to IBD, the definitive role of these viruses in IBD is still a topic of ongoing Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.ibdjournal.org).
controversy. human herpes virus 6 (HHV6) has also been studied, with some studies demonstrating the presence of HHV6 DNA in the inflamed mucosa of Crohn's disease (CD) and ulcerative colitis (UC) patients, 11 although no definitive evidence had been established between these 2 entities. 12 The detection of these agents in blood or mucosa of patients with IBD remains a clinical challenge, being hard to distinguish between a superimposed infection and a disease relapse. 8 Recent data had highlighted the need and interest of quantifying mucosal viral load by real time polymerase chain reaction to achieve the correct diagnosis and establish proper management. 13, 14 This study aims to evaluate the prevalence and viral load of EBV, CMV, and HHV6 in the blood and mucosa (both inflamed and noninflamed) of adult patients with active endoscopic IBD; and to assess the influence of different therapeutic regimens on viral prevalence. To our knowledge, this is the first study to address simultaneously the detection of EBV, CMV, and HHV6 in the peripheral blood and mucosa of patients with IBD.
METHODS

Subjects
Consecutive adult patients followed-up at Centro Hospitalar Sao Joao (Porto, Portugal) with endoscopically active IBD were prospectively enrolled between January and December 2014. Patients were included if the following criteria were met: (1) presence of a definitive diagnosis of UC or CD based on accepted clinical, radiological, endoscopic, and histological criteria 15, 16 ; (2) requiring therapy with 5-aminosalicilates (5-ASA), steroids, azathioprine (AZA), methotrexate (MTX), infliximab (IFX), adalimumab (ADA), or any combination of the above; and (3) presence of endoscopic activity, defined by a Simplified Endoscopic Activity Score for CD (SES-CD) $ 3 or Mayo Endoscopic Score for UC $ 2. 17, 18 Patients younger than 18 years, who were pregnant, or did not have endoscopically active disease at the time of the study were excluded. Sex-matched subjects undergoing colonoscopy for colorectal cancer screening who were not taking any of the above drugs served as healthy controls (HCs).
Clinical and demographic data, including age, sex, IBD location and behavior, endoscopic activity, and therapeutic regimen, were collected. Paired peripheral blood and mucosal samples from each patient and HC were obtained at the time of colonoscopy for detection and quantification of EBV, CMV, and HHV6. For patients, mucosal samples were collected from both inflamed (erosions or ulcers) and endoscopically normal (at least 20 cm from the former) areas.
DNA Extraction
EBV nucleic acid extraction used a DNA blood Kit (Qiagen, Inc., Valencia, CA) protocol with EZ1 BioRobot (Qiagen Inc.) from a 200 mL of whole blood sample. For CMV and HHV6, plasma was obtained and 400 mL was extracted by EZ1 virus mini Kit protocol (Qiagen Inc.) using the same robot.
For mucosal samples, biopsies were minced and digested with proteinase K (Qiagen Inc.) at 568C until completely homogenized and DNA was extracted with an automatic processing (QIAcube; Qiagen Inc.) and a spin column protocol (QIAmp DNA mini kit, Qiagen Inc.).
DNA Amplification
CMV, EBV, and HHV6 were amplified using genesig specific kits (Primer Design, Southampton, United Kingdom) and LightCycler 480 II (Roche diagnostics, Indianapolis, IN). To verify the accuracy and sensitivity of virus detection protocols, these kits were at first tested with external quality control panels (Quality control for Molecular Diagnosis, 2013). A calibration curve was obtained for each virus, running, in duplicate, successively diluted positive control samples.
To normalize those several targets quantitative results, tissue samples were submitted to a quantitative parallel PCR reaction targeting a region of the human apoprotein B (ApoB). 19 The DNA obtained from a sample with concentrated and quantified blood leukocytes extraction was diluted, and tested, in duplicate, for ApoB. Because ApoB is encoded by a single gene, the human cells in each tissue sample could be calculated and the virus quantification expressed in copies/10 5 cells.
Statistical Analysis
Categorical variables are described as absolute frequencies (n) and relative frequencies (%). Median and percentiles are used for continuous variables. When testing a hypothesis about continuous variables, nonparametric tests (Mann-Whitney or Kruskal-Wallis) were used as appropriate, taking into account normality assumptions and the number of groups compared. When testing a hypothesis about categorical variables a chi-square test and Fisher's exact test were used, as appropriate. All the reported P values are 2-sided, and P values of ,0.05 were considered statistically significant. Statistical analysis was performed using the software SPSS v.20.0 data (SPSS Inc., Chicago, IL).
Ethical Considerations
This study was conducted according to the Declaration of Helsinki. The study protocols were approved by the Ethics Committee of Centro Hospitalar Sao, Porto, Portugal. Informed 
RESULTS
Patients Characteristics
A total of 95 IBD patients with active endoscopic disease and 50 HCs were enrolled. Forty-three patients had UC (mean age 41.5 6 13.5, 53.5% male), whereas 52 patients had CD (mean age 37.1 6 14.4, 57.7% male). Mean age of HCs was 49.8 6 15.9 years old and 50% were male. At the time of the study, a total of 49 (51.6%) patients were under immunomodulators and 30 (31.6%) under anti-tumor necrosis factor alpha (TNF-a) agents. Eleven patients (9 with CD and 2 with UC) were on steroids at the time of the study. Among the 43 patients with UC, 3 had proctitis, 22 had left-side colitis, and 18 had pancolitis. Of the 42 patients with CD, 14 had ileal, 14 had colonic, 19 had ileocolonic, and 5 had upper gastrointestinal tract involvement (combined with ileal involvement in 2 and ileocolonic in 3). Demographic and clinical data are summarized in Table 1 .
EBV Is the Most Prevalent Viral Agent in Patients with IBD
CMV and EBV DNA were detected more frequently in the mucosa of patients with IBD (CMV DNA 12.1%; EBV DNA 67.0%) compared with HCs (CMV 0%, P ¼ 0.017; EBV 18.0%, P , 0.001). The prevalence of CMV and EBV DNA was similar in patients with CD and UC, and in both groups higher than in HCs (Table 2) . Although CMV DNA was detected in the blood of only 1 patients with IBD and in no HC (P ¼ NS), EBV DNA was detected in the circulation of 20% of both patients and HCs.
Regarding HHV6 DNA, 43% of patients with IBD tested positive in the mucosa (35% CD and 51% UC) and 2% in blood, whereas in HCs, 2% had detectable HHV6 in blood and 28% in the mucosa (P ¼ NS for all comparisons).
When considering the prevalence of the different viruses regarding the presence of ulceration/inflammation of the mucosa, EBV and CMV DNA were more prevalent in inflamed mucosa compared with noninflamed areas, although this difference was only statistically different for EBV both in CD (P ¼ 0.025) and UC (P ¼ 0.019) ( Table 3 & see Table 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B537).
Immunosuppression Does Not Impact on CMV or EBV DNA Prevalence
Because immunosuppression could impact viral prevalence, we analyzed viral prevalence according to current treatment regimens in patients with IBD. The prevalence of CMV, EBV, and HHV6 DNA in both the blood and in the mucosa was similar in patients under therapy with 5-ASA compounds only compared with patients under immunomodulators (either AZA or MTX) and/or anti-TNF-a agents (see Table 2 , Supplemental Digital Content 2, http://links.lww.com/IBD/B538).
EBV median viral load is similar in the inflamed and noninflamed mucosa and does not correlate with endoscopic disease activity.
An analysis comparing viral loads was also performed. Viral load of EBV was higher in inflamed mucosa of patients with CD compared with inflamed mucosa of patients with UC (P ¼ 0.010). There were no significant differences in viral load of CMV and HHV6 in inflamed mucosa of patients with CD compared with inflamed mucosa of patients with UC (P ¼ NS for all comparisons). There were also no significant differences in viral load of EBV and HHV6 in normal mucosa of patients with CD compared with patients with UC (Table 4) . No significant differences were found regarding viral load of CMV, EBV, and HHV6 in ulcerated versus nonulcerated mucosa of patients with CD and UC (Table 5) . When we compared the median values with ranges of DNA copies of all viruses, as obtained by pooling together the data in the IBD group, from both inflamed and noninflamed mucosa, we did not find significantly different values between CD and UC. With respect to EBV and HHV6, when comparing IBD as a group or each disease separately with the control group, no differences were found (Table 6) .
Last, to assess whether viral infections were associated with endoscopic activity, median viral loads were compared according to the SES-CD or the Mayo Endoscopic Score for UC (see Table 3 , Supplemental Digital Content 3, http://links.lww.com/ IBD/B539). The median EBV and HHV6 load was similar in patients with CD with a SES-CD 3 to 9 and those with a score $9. For patients with UC, those with a Mayo score 2 had a EBV, CMV, and HHV6 load that did not differ significantly from patients with a Mayo score 3.
DISCUSSION
In this study, we show that EBV, and to a lesser extent CMV, are prevalent agents in the mucosa of patients with IBD. Their prevalence does not seem to be influenced by the different immunosuppressive regimens. In addition, mucosal viral load does not differ between inflamed and noninflamed mucosa and does not correlate with endoscopic severity of both CD or UC, suggesting that viral agents, more strongly EBV, may play a role in the onset rather than in the severity of IBD.
Despite growing interest in the role of bacterial microbiome dysbiosis in intestinal inflammation, 1 less attention has been drawn to the role of the enteric virome in the pathogenesis of IBD. A recent study showed an alteration in the enteric virome of both CD and patients with UC that seemed to be the contributory factor to intestinal inflammation and bacterial dysbiosis. 20 It is well known that Herpesviridae family is characterized by chronic infection or viral latency after a primary infection, after which the virus may be reactivated. Despite clinical disease being rare in the immunocompetent patient, there are some doubts about the pathogenic effect of these agents under immunosuppressed states: whether they are responsible for the disease and their complications or they are only simple bystanders remains to be defined. 5 Previous studies have attempted to determine the prevalence of different viruses in patients with IBD. Most of them are, however, marred by their retrospective nature, by the inclusion of surgery specimens, and for assessing only one virus at each time. 6, [21] [22] [23] [24] In this study, the detection of EBV, CMV, and HHV6 in the peripheral blood and mucosa of patients with IBD was addressed simultaneously for the first time. Herein, we show that the prevalence of EBV and CMV DNA in peripheral blood does not differ between HCs and patients with IBD, but a higher prevalence of EBV, and to a lesser extent of CMV, was found in the mucosa of patients with IBD compared with HCs. In accordance with the results reported by others, we also found EBV as the most prevalent agent, with 2/3 of patients with IBD showing positivity for EBV. 14 Also, noteworthy is the finding of a higher prevalence of viral DNA in intestinal mucosa compared with the peripheral blood. This may suggest a potential role for EBV and CMV in the immune disturbance present on intestinal mucosa; alternatively, in case of CMV, it may only reflect its known tropism for inflammatory cells. 25 Despite previous studies focused on the role of CMV in UC, 21, 23 in this study, we only found a higher prevalence in diseased mucosa for EBV, both in CD and UC. However, when analyzing the EBV viral load within the IBD group of patients, the median values were not found to be significantly higher in diseased versus nondiseased mucosa. The observation that EBV is equally found in inflamed and noninflamed mucosa, suggests its role as a trigger of IBD rather than causing a superimposed infection. Because of the inexistence of CMV DNA in normal mucosa, and the very low viral load in inflamed mucosa, no conclusion could be drawn regarding CMV infection.
The possible role of viruses as trigger(s) of IBD is further supported by the absence of correlation between the mucosal viral load and the degree of endoscopic activity. Even in normal mucosa, there were no significant differences in the median viral DNA levels in patients with IBD compared with the control group.
On the other hand, HHV6 seemed to have no role in the pathogenesis of IBD, as prevalence and viral load was similar between the IBD population and the control group, suggesting that not all viruses are associated with IBD pathogenesis.
In contrast to published evidence of a significantly increased risk of EBV and CMV reactivation under immunomodulator therapy, 6, 26 we did not find any positive relation between both anti-TNF a and/or AZA/MTX use and viral prevalence. In a previous study by our group, 6 where we aimed to evaluate EBV prevalence in the blood of patients with IBD at remission and compare that with the general population, we found that reactivation of EBV is more frequent among patients with IBD and that therapeutic regimen did influence the prevalence of EBV. Although the methodology used to detect EBV DNA in both studies were the same, in the current study, we have included patients with endoscopically active disease only, and therefore, we were not able to reproduce such finding. In addition, although in the 2013 study the mean age of the control group was 35 years, in the current it was 49.8 years 6 ; the age difference between the 2 studies was because of ethical constraints in obtaining intestinal mucosa from healthy subjects younger than 50 years. In line with the current study, there are studies suggesting that only steroids and anti-TNF-a agents are associated with EBV colitis, but not the use of immunosuppressants or the duration of therapy. 14 In summary, we provide evidence that EBV, and to a lesser extent CMV, are prevalent in patients with IBD, and that their prevalence is not affected by different therapeutic regimens. In addition, mucosal viral load does not differ between inflamed and noninflamed mucosa, and does not seem to be influenced by the endoscopic activity of the disease. Taken together, these data support a putative role of certain viral agents, most notably EBV, in IBD pathogenesis and suggest that their frequent detection is not associated with either disease severity or superimposed infection. A note of caution, however, should be made when trying to extrapolate the findings obtained from our patients' cohort that included patients with endoscopically active disease, a relatively high proportion of subjects under immunomodulators and/or anti-TNF-a agents, to IBD population in general. Larger studies are needed to address other potential caveats (i.e., age at disease onset) and make these investigations more readily applicable.
